Aspirin and urologic cancer risk

An update

Cristina Bosetti, Valentina Rosato, Silvano Gallus, Carlo La Vecchia

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aspirin has been associated with a reduced risk of colorectal cancer. With specific reference to urological cancers, a protective role for aspirin has been suggested for prostate cancer, but data for cancers of the bladder and kidney have been limited and inconsistent. Epidemiological evidence suggests that prostate cancer risk is reduced by 10% in regular aspirin users, with similar risk reductions reported in both case-control and cohort studies, and for both slow-growing and aggressive cancers. However, risk estimates were significantly heterogeneous and there was no relationship between risk reduction and frequency, dose or duration of use. Thus, inference for causality and public health implications remain far from conclusive. Although a few case-control studies have reported a favorable effect of aspirin on bladder cancer, most investigations did not find any meaningful association. A modest nonsignificant increased risk was reported for kidney cancer. Such excess risk, however, might be due to exposure to phenacetin-containing analgesics, which have been reported to increase renal cell cancer risk.

Original languageEnglish
Pages (from-to)102-110
Number of pages9
JournalNature Reviews Urology
Volume9
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Urologic Neoplasms
Aspirin
Kidney Neoplasms
Risk Reduction Behavior
Urinary Bladder Neoplasms
Case-Control Studies
Prostatic Neoplasms
Phenacetin
Renal Cell Carcinoma
Causality
Analgesics
Colorectal Neoplasms
Cohort Studies
Public Health
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Aspirin and urologic cancer risk : An update. / Bosetti, Cristina; Rosato, Valentina; Gallus, Silvano; La Vecchia, Carlo.

In: Nature Reviews Urology, Vol. 9, No. 2, 02.2012, p. 102-110.

Research output: Contribution to journalArticle

Bosetti, Cristina ; Rosato, Valentina ; Gallus, Silvano ; La Vecchia, Carlo. / Aspirin and urologic cancer risk : An update. In: Nature Reviews Urology. 2012 ; Vol. 9, No. 2. pp. 102-110.
@article{d85677a6fb3c4ada8597d0fb014edd32,
title = "Aspirin and urologic cancer risk: An update",
abstract = "Aspirin has been associated with a reduced risk of colorectal cancer. With specific reference to urological cancers, a protective role for aspirin has been suggested for prostate cancer, but data for cancers of the bladder and kidney have been limited and inconsistent. Epidemiological evidence suggests that prostate cancer risk is reduced by 10{\%} in regular aspirin users, with similar risk reductions reported in both case-control and cohort studies, and for both slow-growing and aggressive cancers. However, risk estimates were significantly heterogeneous and there was no relationship between risk reduction and frequency, dose or duration of use. Thus, inference for causality and public health implications remain far from conclusive. Although a few case-control studies have reported a favorable effect of aspirin on bladder cancer, most investigations did not find any meaningful association. A modest nonsignificant increased risk was reported for kidney cancer. Such excess risk, however, might be due to exposure to phenacetin-containing analgesics, which have been reported to increase renal cell cancer risk.",
author = "Cristina Bosetti and Valentina Rosato and Silvano Gallus and {La Vecchia}, Carlo",
year = "2012",
month = "2",
doi = "10.1038/nrurol.2011.219",
language = "English",
volume = "9",
pages = "102--110",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Aspirin and urologic cancer risk

T2 - An update

AU - Bosetti, Cristina

AU - Rosato, Valentina

AU - Gallus, Silvano

AU - La Vecchia, Carlo

PY - 2012/2

Y1 - 2012/2

N2 - Aspirin has been associated with a reduced risk of colorectal cancer. With specific reference to urological cancers, a protective role for aspirin has been suggested for prostate cancer, but data for cancers of the bladder and kidney have been limited and inconsistent. Epidemiological evidence suggests that prostate cancer risk is reduced by 10% in regular aspirin users, with similar risk reductions reported in both case-control and cohort studies, and for both slow-growing and aggressive cancers. However, risk estimates were significantly heterogeneous and there was no relationship between risk reduction and frequency, dose or duration of use. Thus, inference for causality and public health implications remain far from conclusive. Although a few case-control studies have reported a favorable effect of aspirin on bladder cancer, most investigations did not find any meaningful association. A modest nonsignificant increased risk was reported for kidney cancer. Such excess risk, however, might be due to exposure to phenacetin-containing analgesics, which have been reported to increase renal cell cancer risk.

AB - Aspirin has been associated with a reduced risk of colorectal cancer. With specific reference to urological cancers, a protective role for aspirin has been suggested for prostate cancer, but data for cancers of the bladder and kidney have been limited and inconsistent. Epidemiological evidence suggests that prostate cancer risk is reduced by 10% in regular aspirin users, with similar risk reductions reported in both case-control and cohort studies, and for both slow-growing and aggressive cancers. However, risk estimates were significantly heterogeneous and there was no relationship between risk reduction and frequency, dose or duration of use. Thus, inference for causality and public health implications remain far from conclusive. Although a few case-control studies have reported a favorable effect of aspirin on bladder cancer, most investigations did not find any meaningful association. A modest nonsignificant increased risk was reported for kidney cancer. Such excess risk, however, might be due to exposure to phenacetin-containing analgesics, which have been reported to increase renal cell cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=84857030611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857030611&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2011.219

DO - 10.1038/nrurol.2011.219

M3 - Article

VL - 9

SP - 102

EP - 110

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 2

ER -